Merkel cell carcinoma (MCC) is more deadly and resource-intensive than many other cancers. A Mayo Clinic study of over 1,000 MCC patients found significantly higher hospitalization rates, more critical care admissions, and worse survival outcomes compared to matched patients without MCC. MCC also fared worse than melanoma, breast, and prostate cancers in terms of outcomes.
Merkel cell carcinoma (MCC) — a rare and aggressive skin cancer — is taking a serious toll on patients and the healthcare system, according to a new Mayo Clinic study. Researchers compared over 1,000 MCC patients against matched individuals without MCC and those with other cancers, finding that MCC patients faced significantly higher rates of hospitalization, critical care admissions, and overall mortality.
Survival rates told a stark story: only 45.4% of MCC patients were alive at 10 years, compared to 73.8% of matched non-MCC patients. MCC outcomes were worse than melanoma, breast, and prostate cancers, though better than lung cancer, colorectal cancer, and glioblastoma. Patients with MCC also carried a heavier comorbidity burden, including higher rates of immunodeficiencies, hematologic disorders, and cardiovascular disease.
By the Numbers:
Why it matters: MCC is often underestimated relative to more common cancers, but this study underscores its outsized impact on patient health and healthcare resources — making early detection and targeted management strategies all the more critical.
